GlassScriptPhysician profile
John E Loudermilk
NPI 1780996918
$2,938.30
in general payments reported to CMS, 2019-2025
25 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.39 · 2020: $69.85 · 2021: $378 · 2022: $720 · 2023: $729 · 2024: $596 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $518.02 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $402.58 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $352.17 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $339.19 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.32 | 2022-2025 | |
| Abbott Laboratories | $141.12 | 2023-2025 | Mitraclip, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $134.75 | 2020-2025 | Farxiga, Airsupra |
| Acclarent, INC | $117.06 | 2023 | Acclarent Aera |
| Dexcom, INC. | $98.16 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.76 | 2021-2023 | Jardiance |
| Abbvie INC. | $84.08 | 2022-2025 | |
| Boston Scientific Corporation | $73.92 | 2023-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $68.08 | 2021-2024 | |
| Amarin Pharma, INC. | $65.88 | 2021-2022 | |
| Amgen INC. | $57.97 | 2021-2024 | Evenity, Prolia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.37 | 2022-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $40.30 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $35.88 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $32.77 | 2023 | Belsomra, Januvia, Steglatro |
| Eisai INC. | $21.21 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.12 | 2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $16.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.90 | 2024 | Voquezna |
| Exact Sciences Corporation | $13.93 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Loudermilk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.